Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Multiple Sclerosis

Volumn 16, Issue 11, 2010, Pages 1385-1392

  Morrow, S A ^a   O'Connor, P W ^b   Polman, C H ^c   Goodman, A D ^d   Kappos, L ^e   Lublin, F D ^f   Rudick, R A ^g   Jurgensen, S ^h   Paes, D ^h   Forrestal, F ^h   Benedict, R H B ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h BIOGEN   (United States)

Author keywords

cognition; multiple sclerosis; screening

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; EFFECT SIZE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS NEUROPSYCHOLOGICAL SCREENING QUESTIONNAIRE; NEUROPSYCHOLOGICAL TEST; QUESTIONNAIRE; SYMBOL DIGIT MODALITIES TEST; TEST RETEST RELIABILITY; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; COGNITION DISORDERS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES;

EID: 78449297684     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510378021     Document Type: Article

References (27)

1. Rao SM, Leo GJ, Bernardin L. and Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991 ; 41: 685-691.
2. Benedict RH, Cookfair D., Gavett R., et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006 ; 12: 549-558.
3. Benito-Leon J., Morales JM and Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002 ; 9: 497-502.
4. Benedict RHB, Wahlig E., Bakshi R., et al. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005 ; 231: 29-34.
5. Amato MP, Ponziani G., Rossi F., Liedl CL, Stefanile C. and Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001 ; 7: 340-344.
6. Rao SM, Leo GJ, Ellington L., Nauertz T., Bernardin L. and Unveragt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991 ; 41: 692-696.
7. Benedict RHB, Cox D., Thompson LL, Foley FW, Weinstock-Guttman B. and Munschauer F. Reliable screening for neuropsychological impairment in MS. Mult Scler 2004 ; 10: 675-678.
8. Benedict RHB and Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006 ; 245: 67-72.
9. Scherer P. Cognitive screening in multiple sclerosis. J Neurol 2007 ; 254 (Suppl 2): 1126-1129.
10. Foley JF and Brandes DW Redefining functionality and treatment efficacy in multiple sclerosis. Neurology 2009 ; 72 (23 Suppl 5). S1-11.
11. Benedict RH, Duquin JA, Jurgensen S., et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 2008 ; 14: 940-946.
12. Munschauer F., Benedict RHB, Granger CV and Niewczyk PM Introduction to best practice recommendations for the selection and management of patients with MS on natalizumab. Mult Scler 2009 ; 15 (S4). 1-6.
13. Tornatore C. and Clifford DB Clinical vigilance for progressive multifocal leukoencephalopahty in the context of natalizumab use. Mult Scler 2009 ; 15 (S4). 16-25.
14. Polman CH, O'Connor PW, Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
15. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 911-923.
16. Goodman AD, Rossman H., Bar-Or A., et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009 ; 72: 806-812.
17. Lunceford JK and Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004 ; 23: 2937-2960.
18. 'Agostino Jr RB Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 ; 17: 2265-2281.
19. Yanovitzky I., Zanutto E. and Hornik R. Estimating causal effects of public health education campaigns using propensity scores methodology. Eval Program Plann 2005 ; 28: 209-220.
20. Benedict RHB, Munschauer FE, Linn R., Miller C., Foley FW and Jacobs LD Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 2003 ; 9: 95-101.
21. Duque B., Sepulcre J., Bejarano B., Samaranch L., Pastor P. and Villoslada P. Memory decline evolves independently of disease activity in MS. Mult Scler 2008 ; 14: 947-953.
22. Brochet B., Deloire MS, Bonnet M., et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler 2008 ; 14: 1242-1249.
23. Howard GS and Dailey PR Response-shift bias: a source of contamination of self-report measures. J Appl Psychol 1979 ; 64: 144-150.
24. Schwartz CE Teaching coping skills enhances quality of life more than peer support: results of a randomized trail with multiple sclerosis patients. Health Psychol 1999 ; 18: 211-220.
25. Benedict RHB, Carone D. and Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging 2004 ; 14 (Suppl 3): 36S-45S.
26. Carone D., Benedict RHB, Munschauer III FE, Fishman I. and Weinstock-Guttman B. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J Int Neuropsychol Soc 2005 ; 11: 574-583.
27. Benedict RH and Benedict RH B. Effects of using same-versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. J Int Neuropsychol Soc 2005 ; 11: 727-736.